Arnason JE, Brown JR. Alemtuzumab use in relapsed and refractory chronic lymphocytic lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:119–120.

On page 119 in the Hematology 2011 Education Program Book, there is an error in the title and in the first sentence of the Abstract; the word “lymphoma” should have read “leukemia.” The title reads “Alemtuzumab use in relapsed and refractory chronic lymphocytic lymphoma” but should read “Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia.” The first sentence of the Abstract reads, “A 62-year-old woman with chronic lymphocytic lymphoma (CLL) who initially presented with lymphocytosis and 13q deletion in 1996 now presents to the clinic for recommendations regarding relapsed disease.” The sentence should have read, “A 62-year-old woman with chronic lymphocytic leukemia (CLL) who initially presented with lymphocytosis and 13q deletion in 1996 now presents to the clinic for recommendations regarding relapsed disease.” The errors have been corrected in the online version, which now differs from the print version.